The funding highlights how service robotics is shifting from niche deployments to scaled commercial use across global markets
Updated
April 24, 2026 2:26 PM
An autonomous service robot with a cat face design standing inside a McDonalds restaurant. PHOTO: ADOBE STOCK
Pudu Robotics, a Shenzhen-based startup building robots for commercial environments, has raised nearly US$150 million in a new funding round, pushing its valuation past US$1.5 billion. The raise brings the company’s total funding to more than US$300 million.
The company focuses on service robotics across sectors such as delivery, cleaning and industrial logistics. Its systems are used in places like retail stores, warehouses and public venues where routine tasks can be automated. Over time, Pudu has expanded from single-purpose machines to a broader portfolio that combines hardware with AI-driven navigation and coordination.
The funding is expected to support several areas of growth. These include further development of its AI systems, expansion of its product range and continued international rollout. The company also plans to invest in manufacturing and supply chain capacity, suggesting a focus on scaling production alongside demand.
Pudu’s recent growth provides some context for the raise. The company reported a doubling of revenue by 2025, with its cleaning robots now accounting for the majority of its business. Its industrial delivery robots have also seen early traction, with thousands of units deployed within a year of launch.
Its products are already in use with large global retailers including Carrefour, Walmart and EDEKA. Industry estimates place Pudu among the largest players in commercial service robotics, with a leading share of the global market.
Technically, the company develops much of its core stack in-house, including navigation systems, multi-robot coordination software and motion control. This allows its robots to operate in complex real-world environments where multiple machines need to move and work together.
“This financial milestone is a powerful confirmation of Pudu’s industry leadership, the strength of its products and technology, its global brand, and its commercial infrastructure. With the support of our strategic investors and industry partners, Pudu will continue to push the boundaries of embedded AI and business service robotics. We remain committed to innovating with an inventor’s spirit and leveraging a global vision to accelerate robot adoption, thereby elevating the industry to new heights in the global value chain”. said Felix Zhang, founder and CEO of Pudu Robotics.
The funding round points to a broader shift in the sector. As service robotics moves from pilot deployments to wider adoption, companies are increasingly being judged on their ability to scale production and operate across markets, not just on the novelty of their technology.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.